Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

25

Revenue 2017

CSL

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of CSL's 2013 sales performance.

Takeda’s HAE drug Takhzyro backed by NICE

Takeda’s HAE drug Takhzyro backed by NICE

First-line preventive treatment is with oral drugs like danazol and oxandrolone, and with C1 esterase inhibitors like Takeda’s intravenous Cinryze and CSL Behring’s injectable Berinert that are also

EMA clears Novo Nordisk’s long-acting haemophilia A drug

EMA clears Novo Nordisk’s long-acting haemophilia A drug CSL Behring with Afstyla, so Esperoct has direct competition right off the bat.

Drug launches to watch in 2019

Drug launches to watch in 2019 At the moment Shire’s big competitor in HAE is CSL with its Haegarda product, a subcutaneous medicine that launched last year and has been trying to steal market share from

Shire’s angioedema drug Takhzyro claims EU approval

Shire’s angioedema drug Takhzyro claims EU approval The switchovers includes some patients on Cinryze but also competitors’ products, he said.  At the moment Shire’s big competitor in HAE is CSL with its Haegarda product, a subcutaneous medicine

Shire’s angioedema drug Takhzyro recommended in Europe

Shire’s angioedema drug Takhzyro recommended in Europe The drug isn’t the first HAE treatment on the market, however: CSL’s subcutaneous therapy Haegarda gained approval in 2017 - despite Shire's legal efforts to block it with claims ... CSL’s drug has showed a median reduction in monthly attacks of

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics